Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials

@article{Biglia2010TiboloneIP,
  title={Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials},
  author={Nicoletta Biglia and Silvia Maffei and Stefano Lello and Rossella Elena Nappi},
  journal={Gynecological Endocrinology},
  year={2010},
  volume={26},
  pages={804 - 814}
}
Aim. To critically discuss the use of tibolone (T), in light of a series of very recent double-blind placebo (PL) controlled trials (LISA, LIFT, OPAL, THEBES, LIBERATE) conducted worldwide in a large number of postmenopausal women (PMW). Methods. The most relevant publications on T therapy in PMW were considered with emphasis on menopausal symptoms, quality of life, sexuality, bone, cardiovascular system (CVS) and oncologic risk. Results. T significantly relieves climacteric symptoms and… Expand
Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients.
TLDR
This meta-analysis shows that oral tibolone treatment significantly lowers circulating Lp(a) levels in postmenopausal women and the potential value and place of tIBolone or its analogues in the treatment of elevated Lp (a) in individuals at risk of CVD. Expand
Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial.
TLDR
After 12 weeks of Tibolone use, the total score and percentage of the KMI and GCS were significantly decreased compared to baseline, which reflected the efficacy of the treatment of climacteric symptoms and the absence of serious side effects demonstrated good tolerability. Expand
Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial
TLDR
After 12 weeks of Tibolone use, the total score and percentage of the Blatt-Kupperman Menopausal Index and the Greene Climacteric Scale were significantly decreased compared to baseline, which reflected the efficacy of the treatment of climacteric symptoms. Expand
Effects of Tibolone on the Central Nervous System: Clinical and Experimental Approaches
TLDR
TIB has important neuroprotective effects that could prevent the risk of neurodegenerative diseases in postmenopausal women as well as the benefits of HRT in counteracting hot flashes, improving mood, and libido. Expand
Cardiovascular Risk/Benefit Profile of MHT
TLDR
Timing of MHT initiation was shown to be a critical factor in CV risk assessment and CV risk calculation should be considered by clinicians in order to exclude patients with high CV risk, in whom MHT is contraindicated. Expand
Pharmacotherapeutic options for the treatment of menopausal symptoms
TLDR
The pharmacokinetics and pharmacodynamics of hormonal (androgens, estrogens, progestogens, tibolone, TSEC, SERMs) and non-hormonal treatments for menopausal symptoms are described and essential clinical trial data in humans is reported. Expand
Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta‐analysis of controlled trials
TLDR
Meta‐analysis did not suggest a significant reduction of fibrinogen and ATIII levels following treatment with tibolone, and this result was robust in the sensitivity analysis and not influenced after omitting each of the included studies from meta‐analysis. Expand
Progestogens in postmenopausal hormone therapy and the risk of breast cancer.
TLDR
Both the type of the progestogen and the mode of HT administration may have an impact on breast cancer risk, convincing evidence from both clinical trials and epidemiological studies indicates. Expand
Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society
  • Medicine
  • Menopause
  • 2021
Abstract Objective: To review evidence regarding osteoporosis screening, prevention, diagnosis, and management in the past decade and update the position statement published by The North AmericanExpand
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review
TLDR
Vaginal dehydroepiandrosterone, hypothesized to enhance local production of both androgen and estrogen, is effective for the management of dyspareunia in menopause, but more studies are needed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 108 REFERENCES
Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
TLDR
Tibolone is a valuable treatment option for women with climacteric complaints and might be preferable to EPT in certain women who have not been hysterectomised, and has positive effects on sexual well-being and mood. Expand
The effects of tibolone in older postmenopausal women.
TLDR
Tibolone reduced the risk of fracture and breast cancer and possibly colon cancer but increased therisk of stroke in older women with osteoporosis and the study was stopped at the recommendation of the data and safety monitoring board. Expand
Tibolone for postmenopausal women: systematic review of randomized trials.
TLDR
The results from the randomized, controlled, and double blind trials of tibolone are discussed, with respect to its effects on climacteric symptoms, sexual function, endometrial and breast tissue, lipid metabolism, and bone mineral density. Expand
Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.
TLDR
The LIBERATE trial was designed as a randomized, double-blind, multicenter trial to demonstrate that tibolone 2.5mg/day (Livial) is non-inferior to placebo regarding BC recurrence in women with vasomotor symptoms surgically treated for primary BC within the last 5 years. Expand
Endometrial effects of tibolone.
TLDR
The Tibolone Histology of the Endometrium and Breast Endpoints Study results confirm previous findings that tibolone does not induce endometrial hyperplasia or carcinoma in postmenopausal women, and it is associated with a better vaginal bleeding profile than CEE/MPA. Expand
Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches
TLDR
In postmenopausal headache sufferers, analgesics are more effective in alleviating severe head pain when women are treated with T in comparison with low-dose EPT for climacteric complaints. Expand
Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women.
TLDR
The combined regimen of androgens and ERT increased vertebral bone mass and enhance sexual activity in postmenopausal women equal to that of tibolone and to a greater extent than ERT alone; its effects on lipids, however, are clearly adverse. Expand
A study of the effect of tibolone on the vagina in postmenopausal women.
TLDR
It is concluded that tibolone has a significant oestrogenic effect on the vagina as demonstrated by vaginal cytology and improvement in the symptoms of vaginal dryness, dyspareunia, sexual enjoyment and libido occurs. Expand
The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).
TLDR
The addition of tibolone to GnRH-a treatment reduces the bone loss and vasomotor symptoms that normally occur with Gn RH-a, thus making long-term treatment with Gnrh-a safer and more acceptable. Expand
Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer
TLDR
Tibolone was effective in the treatment of climacteric symptoms and well tolerated in a group of 52 women with a history of breast cancer and the cancer recurrence rate in the tibolones group was comparable to that of untreated controls. Expand
...
1
2
3
4
5
...